Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 50%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Amifostine vs no treatment/placebo

Vomiting · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine may leads to higher vomiting (adverse effect) compared with no treatment/placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
RR 4.90 [2.87, 8.38]
5 studies · 601 participants
Low

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Vomiting · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine 200 mg/m2 three times weekly showed no clear difference in vomiting (adverse effect) compared with amifostine 200 mg/m2 five times weekly; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
RR 0.25 [0.06, 1.08]
1 study · 60 participants
GRADE not reported